Nathan D M, Fogel H, Norman D, Russell P S, Tolkoff-Rubin N, Delmonico F L, Auchincloss H, Camuso J, Cosimi A B
Diabetes, Unit, Massachusetts General Hospital, Boston.
Transplantation. 1991 Jul;52(1):85-91. doi: 10.1097/00007890-199107000-00018.
Evaluation of whole-organ pancreas transplantation in the therapy of IDDM has been difficult because of generally poor graft survival and significant complications in past experience. We report a technically successful simultaneous pancreas/kidney transplant program with patient and graft survival of 85% over 3 years of follow-up (mean 21 months) in 33 subjects with IDDM. Glucose metabolism was normalized without need for exogenous insulin immediately posttransplant in all but one recipient and remained normal in 85% of recipients. The outcome in pancreas/kidney recipients was compared with that in 18 insulin-dependent diabetic recipients of kidney transplant only performed in the same period. Quality of life was assessed with one general and one diabetes-specific questionnaire. General quality of life issues improved significantly in both pancreas/kidney and kidney recipients, but diabetes specific quality of life improved only in the pancreas/kidney recipients. Pancreas/kidney recipients required twice as long a period of hospitalization for the transplant and two times as many readmissions for a variety of complications. Only a minority of hospital admissions was strictly attributable to the pancreas graft. Of the five deaths in the pancreas/kidney recipients, two were attributable to the pancreas transplant. Pancreas transplantation in IDDM can now be accomplished with a high degree of success, resulting in normalized glucose metabolism and with overall mortality similar to kidney transplantation alone. Successful pancreas transplantation improves quality of life with respect to diabetes but this benefit is accomplished at a cost of increased hospital admissions and complications related to the transplanted pancreas. The effects of pancreas transplantation on the long-term complications of insulin-dependent diabetes remain unknown.
由于过去经验中移植物总体存活率低且并发症严重,评估全器官胰腺移植治疗胰岛素依赖型糖尿病(IDDM)一直很困难。我们报告了一项技术上成功的同期胰肾联合移植项目,在33例IDDM患者中,随访3年(平均21个月)患者和移植物存活率达85%。除1例受者外,所有受者移植后血糖代谢立即恢复正常,无需外源性胰岛素,85%的受者血糖维持正常。将胰肾联合移植受者的结果与同期仅接受肾移植的18例胰岛素依赖型糖尿病受者的结果进行比较。用一份通用问卷和一份糖尿病专用问卷评估生活质量。胰肾联合移植受者和肾移植受者的总体生活质量问题均有显著改善,但糖尿病特异性生活质量仅在胰肾联合移植受者中有所改善。胰肾联合移植受者移植所需住院时间是肾移植受者的两倍,因各种并发症再次入院的次数也是两倍。只有少数住院是完全归因于胰腺移植物的。在胰肾联合移植受者的5例死亡中,2例归因于胰腺移植。IDDM患者的胰腺移植现在可以高度成功地完成,使血糖代谢正常化,总体死亡率与单纯肾移植相似。成功的胰腺移植改善了与糖尿病相关的生活质量,但这一益处是以增加住院次数和与移植胰腺相关的并发症为代价的。胰腺移植对胰岛素依赖型糖尿病长期并发症的影响尚不清楚。